Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies

Introduction: Lazertinib is a potent, irreversible, brain-penetrant, mutant-selective, and wild-type–sparing third-generation EGFR tyrosine kinase inhibitor (TKI), creating a wide therapeutic index. Cardiovascular adverse events (AEs), including QT prolongation, decreased left ventricular ejection f...

Full description

Bibliographic Details
Main Authors: Seong Bok Jang, PhD, Kyeong Bae Kim, PhD, Sujin Sim, MS, Byoung Chul Cho, MD, PhD, Myung-Ju Ahn, MD, PhD, Ji-Youn Han, MD, PhD, Sang-We Kim, MD, PhD, Ki Hyeong Lee, MD, PhD, Eun Kyung Cho, MD, PhD, Nahor Haddish-Berhane, PhD, Jaydeep Mehta, PharmD, PhD, Se-Woong Oh, PhD
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Tyrosine kinase inhibitor
Lazertinib
Cardiac toxicity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000837

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000837

Similar Items